Oruka Therapeutics

Oruka Therapeutics (operating at orukatx.com) is a biopharmaceutical company pioneering novel biologics to redefine treatment standards for chronic skin diseases. Founded by seasoned biopharma professionals and drug developers, the company is headquartered in Baltimore, Maryland, though its clinical operations span North America. Unlike conventional therapies that often fall short in addressing plaque psoriasis and psoriatic arthritis, Oruka’s approach focuses on developing targeted biologics designed to restore skin health and improve patient quality of life. Their pipeline centers on ORKA-002, a first-in-class therapeutic undergoing clinical trials to demonstrate efficacy in dose-ranging studies. This precision-driven methodology empowers dermatologists and rheumatologists to offer more effective, personalized care to patients suffering from debilitating conditions. Backed by substantial private financing, including an $180 million PIPE round led by Viking Global Investors and participation from Affinity, Oruka is poised to accelerate its clinical development with additional funding from a proposed $500 million underwritten offering.